BTG2 and neoplasm: In the M6A-dependent pathway, VIRMA regulates key oncogenes (e.g., FOXM1, HK2) and tumor suppressor genes (e.g., RND3, BTG2), affecting the proliferation, metastasis, metabolic reprogramming, and drug resistance of tumor cells [18,24,39].